China vs Sudan: Average cost of multi drug-resistant tuberculosis treatment
China
20,028 constant 2022 US$
in 2024
Sudan
51,726 constant 2022 US$
in 2023
China rank
4th
Sudan rank
1st
Average cost of multi drug-resistant tuberculosis treatment over time
- China
- Sudan
How they compare
Sudan currently reports 51,726 constant 2022 US$ against 20,028 constant 2022 US$ in China, a difference of 31,698 constant 2022 US$.
That makes Sudan's figure about 2.6 times China's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Sudan ahead.
China ranks 4th and Sudan ranks 1st of 92 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,001 constant 2022 US$ | 2,275 constant 2022 US$ | 3,726 constant 2022 US$ | China |
| 2020s | 20,512 constant 2022 US$ | 13,796 constant 2022 US$ | 6,716 constant 2022 US$ | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, China or Sudan?
- Sudan, at 51,726 constant 2022 US$ against 20,028 constant 2022 US$ in China as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between China and Sudan?
- 31,698 constant 2022 US$, with Sudan ahead.
- How many years of comparable data are there for China and Sudan?
- 7 years are reported by both, from 2017 to 2023.
- How do China and Sudan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- China ranks 4th and Sudan ranks 1st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.